PJPaul R. Johnson

Paul R. Johnson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paul R. Johnson has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cortisol as a Biomarker for Stress During the Assessment and Treatment of Destructive Behavior

    by Sean W. Smith, Paul R. Johnson, William E. Sullivan, Courtney R. Mauzy, Beatriz E. Arroyo Antúnez, Andrew R. Craig, Alexandra R. Howard, Thanh Nguyen, Chelsea Hoffman, Samhitha Adavikolanu, et al.

    Behavior-analytic treatments successfully reduce individuals’ destructive behavior (e.g., self-injurious behavior, aggression, property destruction, disruption); however, there is limited research evaluating these treatments’ effects on individuals’ physiological stress responses, even though stress can have significant negative impacts on quality of life. Research from other fields has demonstrated that salivary cortisol concentration is a valid biomarker for stress, so researchers could potentially use this biomarker to assess the stress of individuals with limited communication repertoires who also engage in destructive behavior. The purpose of this research was to assess changes in salivary cortisol concentrations as a biomarker for stress with two participants to evaluate whether conditions that evoke destructive behavior induce stress relative to conditions that do not evoke destructive behavior. For one participant, salivary cortisol concentrations tended to increase following exposures to stimuli that evoked destructive behavior compared to conditions that did not evoke destructive behavior. The other participant had elevated salivary cortisol concentrations across all conditions. Salivary cortisol may be a useful biomarker for evaluating physiological stress as an outcome measure during research on the assessment and treatment of destructive behavior.


  • Managing biological variation data: modern approaches for study design and clinical application

    by Paul R. Johnson, Shahram Shahangian, J. Rex Astles

    For more than one half-century, variability observed in clinical test result measurements has been ascribed to three major independent factors: (i) pre-analytical variation, occurring at sample collection and processing steps; (ii) analytical variation of the test method for which measurements are taken, and; (iii) biological variation (BV). Appreciation of this last source of variability is the major goal of this review article. Several recent advances have been made to generate, collate, and utilize BV data of biomarker tests within the clinical laboratory setting. Consideration of both prospective and retrospective study designs will be addressed. The prospective/direct study design will be described in accordance with recent recommendations discussed in the framework of a newly-developed system of checklist items. Potential value of retrospective/indirect study design, modeled on data mining from cohort studies or pathology laboratory information systems (LIS), offers an alternative approach to obtain BV estimates for clinical biomarkers. Moreover, updates to BV databases have made these data more current and widely accessible. Principal aims of this review are to provide the clinical laboratory scientist with a historical framework of BV concepts, to highlight useful applications of BV data within the clinical laboratory environment, and to discuss key terms and concepts related to statistical treatment of BV data.


  • Open Access

    Comparison of serum and saliva miRNAs for identification and characterization of mTBI in adult mixed martial arts fighters

    by Daria LaRocca, Sarah Barns, Steven D Hicks, Andrew Brindle, Jeremy Williams, Richard Uhlig, Paul Johnson, Christopher Neville, Frank A Middleton

    Traumatic brain injury (TBI) is a major cause of death and disability worldwide, with mild TBI (mTBI) accounting for 85% of cases. mTBI is also implicated in serious long-term sequelae including second impact syndrome and chronic traumatic encephalopathy. mTBI often goes undiagnosed due to delayed symptom onset and limited sensitivity of conventional assessment measures compared with severe TBI. Current efforts seek to identify accurate and reliable non-invasive biomarkers associated with functional measures relevant to long-term outcomes. Here we evaluated the utility of serum and salivary microRNAs (miRNAs) to serve as sensitive and specific peripheral biomarkers of possible mTBI. Our primary objectives were to establish the relationship between peripheral measures of miRNA, objective quantification of head impacts, and sensitive indices of balance and cognitive function in healthy young adult athletes. A secondary objective was to compare the sensitivity of miRNA versus commonly used blood-based protein biomarkers. 50 amateur mixed martial arts (MMA) fighters participated. 216 saliva and serum samples were collected at multiple time points, both pre- and post-fight. Levels of 10 serum proteins were compared in a subset of the fighters (n = 24). Levels of miRNAs were obtained by next generation sequencing. Functional outcomes were evaluated using a computerized assessment system that measured cognitive performance, body sway, and combined cognitive performance and body sway during dual task completion. Data were analyzed using multivariate logistic regression for predictive classification, analysis of variance, correlation analysis and principal component analysis. We identified a subset of salivary and serum miRNAs that showed robust utility at predicting TBI likelihood and demonstrated quantitative associations with head impacts as well as cognitive and balance measures. In contrast, serum proteins demonstrated far less utility. We also found that the timing of the responses varies in saliva and serum, which is a critical observation for biomarker studies to consider.